We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Toxic Protein Complexes Promote Development of Multiple Neurodegenerative Disorders

By LabMedica International staff writers
Posted on 15 Sep 2008
Neuroscientists have identified a mechanism that explains why patients suffering from severe neurodegenerative diseases such as Alzheimer's disease often develop other syndromes such as Parkinson's disease and vice versa.

The mechanism is linked to the misfolding and pathologic aggregation of neuronal proteins, which has been proposed to play a critical role in the pathogenesis of neurodegenerative disorders. More...
Progressive accumulation of amyloid beta protein (Abeta) oligomers has been identified as one of the central toxic events in Alzheimer's disease, while accumulation of alpha-synuclein (alpha-syn) results in the formation of oligomers and protofibrils in Parkinson's disease.

Investigators from the University of California, San Diego (San Diego, CA, USA) used immunoblots, molecular modeling, and in vitro studies performed with alpha-syn and Abeta in order to understand the molecular mechanisms involved in potential Abeta/alpha-syn interactions. They reported in the September 4, 2008, issue of the journal Public Library of Science (PLoS) ONE that Abeta and alpha-syn co-immunoprecipitated and formed complexes. Molecular modeling and simulations showed that Abeta bound alpha-syn monomers, homodimers, and trimers, forming hybrid ring-like pentamers. Interactions occurred between the N-terminus of Abeta and the N-terminus and C-terminus of alpha-syn. The stable pentamers acted as nanopores that altered neuronal activity and would likely contribute to the mechanisms of neurodegeneration in Alzheimer's and Parkinson's diseases.

"Clinically, we knew that having one neurological disease, such as Alzheimer's, put patients at risk for another neurological disease in combination with it, for example, Parkinson's disease or frontotemporal dementia. But as doctors and scientists, we did not understand why this occurred until now,” explained senior author Dr. Eliezer Masliah, professor of neurosciences and pathology at the University of California, San Diego. "This sort of modeling, to determine the structure of these complexes, was never before possible. With this novel technology, we have come to a new understanding of these combined neurological diseases, and have a model for developing new drugs to treat them.”

Related Links:
University of California, San Diego



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.